Literature DB >> 6479211

The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay.

I J Seppälä, N Routonen, A Sarnesto, P A Mattila, O Mäkelä.   

Abstract

The solid-phase radioimmunoassay for human antibodies was improved so that it gave the total concentration as well as the concentrations of IgM, IgA, IgG1, IgG2, IgG3 and IgG4 antibodies, all seven in the same "L units"/ml. This was accomplished by standardization of monoclonal antibodies with monoisotypic antibodies rather than myelomas; myelomas were found unsatisfactory for this purpose. For the first time it was possible to determine the isotype composition of an antibody population in percent terms. The weight equivalent of the L-unit in one hyperimmune tetanus antitoxin preparation was approximately 7.4 ng. The new solid-phase radioimmunoassay was applied to tetanus toxoid antibodies of the booster response. Total concentrations varied from 1700-26 000 L units/ml (13-200 micrograms/ml). Concentrations of IgG1 antibodies were 1600-25 000 units/ml (average 91% of the total) and concentrations of IgG4 antibodies 12-6900 units/ml (average 6.9% of the total). Antibodies of the other four isotypes were not detected in all sera and together they never exceeded 3% of the total.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6479211     DOI: 10.1002/eji.1830140918

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid.

Authors:  F P Kroon; M J van Tol; C M Jol-van der Zijde; R van Furth; J T van Dissel
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Influence of Gm allotype on the IgG subclass response to streptococcal M protein and outer membrane proteins of Moraxella catarrhalis.

Authors:  R T Carson; D F McDonald; M A Kehoe; J E Calvert
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

3.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

4.  Immunoglobulin subclass distribution of human anti-carbohydrate antibodies: aberrant pattern in IgA-deficient donors.

Authors:  L Hammarström; M A Persson; C I Smith
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

5.  Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally.

Authors:  T Ogawa; H Shimauchi; S Hamada
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

6.  Constant isotype pattern of anti-dsDNA antibodies in patients with systemic lupus erythematosus.

Authors:  T H Winkler; T A Henschel; I Kalies; H W Baenkler; F Skvaril; J R Kalden
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

7.  Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

Authors:  I Julkunen; P Ukkonen; M Stenvik; T Hovi; L Renkonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

8.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

9.  Restriction of human IgG subclass expression in the population of auto-antibodies to glomerular basement membrane.

Authors:  C Bowman; K Ambrus; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy.

Authors:  J J Ballet; G Sulcebe; L J Couderc; F Danon; C Rabian; M Lathrop; J P Clauvel; M Seligmann
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.